PUBLISHER: Polaris Market Research | PRODUCT CODE: 1526389
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1526389
The global cellular starting materials market size is expected to reach USD 9.00 billion by 2032, according to a new study by Polaris Market Research. The report "Global Cellular Starting Materials Market Size, Share, Trends, Industry Analysis Report: Information By Product (Leukopaks, Cells & Tissues), By Grade, By End-Use and By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2024 - 2032." gives a detailed insight into current market dynamics and provides analysis on future market growth.
The cellular starting material market growth is influenced by the advancements in cell culture technologies, which have revolutionized the biopharmaceutical industry by significantly enhancing the efficiency and productivity of cellular production processes. In cell line development, researchers have refined techniques for generating stable and high-producing cell lines through genetic engineering, thereby improving the yield and consistency of biologics. This enables the production of complex molecules like monoclonal antibodies with greater predictability and scalability, meeting the increasing demand in the market.
Moreover, as the cellular starting materials market expands, media formulations have undergone significant advancements. These formulations can now be customized for specific cell types and production requirements. Media formulations deliver precise nutrient levels, growth factors, and regulatory signals essential for robust cell growth and productivity. The evolution towards chemically defined media reduces variability and enhances reproducibility in large-scale bioprocessing. This ensures consistent product quality and adherence to stringent regulatory standards, thereby driving the growth of the market for cellular starting materials.
In addition, researchers are currently investigating adult-derived hematopoietic stem cells for clinical and basic science applications due to their versatility and critical role in stem cell biology. Hematopoietic stem cells (HSCs) and their progenitors are significant sources in regenerative medicine, offering potential treatments for a range of conditions, including non-hematopoietic tissue regeneration and blood disorders. Moreover, rising investments and advancements in cell and gene therapies are anticipated to drive market expansion in this field. For instance, in November 2023, AstraZeneca partnered with Cellectis to advance cell and gene therapy development across oncology, immunology, and rare diseases through gene editing technologies and manufacturing capabilities.
The leukopaks segment accounted for the largest share in 2023 as leukopaks is an essential material in cell based therapies.
The GMP segment held the largest revenue share in the market in 2023 due to rising demand for GMP in biopharmaceutical industries.
North America region dominated the market with the highest revenue share owing to increased investments in R&D, growing interest in cell-based therapies, and enhanced healthcare infrastructure.
The global key market players include AcceGen, AllCells, Anthony Nolan, BioIVT, CGT GLOBAL, Charles River Laboratories, Excellos, HumanCells Bio, NMDP BioTherapies, and STEMCELL Technologies.
Polaris Market Research has segmented the cellular starting materials market report based on type, grade, end-use, and region:
List of Tables:
List of Figures: